Wyndham Wilson

Onyx Wins Backing of FDA Advisory Panel for Cancer Drug

Onyx Pharmaceuticals Inc. gained the most in five years after winning support from a U.S. advisory panel for its drug to treat a deadly blood cancer that affects 50,000 Americans.

Amgen Fails to Win Advisory Panel Backing for Expanded Use of Cancer Drug

Amgen Inc., the world’s biggest biotechnology company, failed to win the backing of a U.S. advisory panel for its drug to delay tumors spreading to bones in patients with advanced prostate cancer.

Panel Backs Glaxo Rare-Cancer Therapy; Rejects Merck Drug

GlaxoSmithKline Plc’s drug for a rare, often deadly form of cancer won the backing of U.S. advisers, while a similar treatment from Merck & Co. and Ariad Pharmaceuticals Inc. failed to gain support.

Affymax Wins U.S. Panel’s Backing on Anemia Drug to Rival Amgen’s Medicine

Affymax Inc. won a U.S. panel’s backing for an experimental anemia medicine that would compete with treatments marketed by Amgen Inc. and Johnson & Johnson for patients with chronic kidney disease.

Affymax Rises After Winning Panel’s Backing for Anemia Drug

Affymax Inc. surged the most in 16 months after winning a U.S. advisory panel’s backing for an experimental anemia medicine that would compete with treatments marketed by Amgen Inc. and Johnson & Johnson.

Pfizer Wins FDA Panel’s Backing for Kidney-Cancer Treatment Axitinib

Pfizer Inc., the world’s biggest drugmaker, won a U.S. panel’s backing for an experimental medicine for advanced kidney cancer in patients who have failed prior treatments.

"This is an unmet need in a group that has really run out of options."

- Wyndham Wilson on Jun 20, 2012

Maryland

New York

California

Silver Spring

Israel to Halt Weapons Flow to Hezbollah, Analyst Says

Berkshire Cash Hits Record $49.1 Billion as Profit Climbs

U.S. Stocks Climb to Record as Jobs Growth Tops Forecasts

Fusion Scientists See Progress as Obama Shows No Ardor

Billionaire Kaiser Exploiting Charity Loophole With Boats